of any ANN. Meijer and colleagues from Hertogenbosch, The Netherlands, report on their results on prostate biopsy predicting model of the ANN Prostataclass of the Universitätsklinikum Charité, Berlin, Germany, from their database.
Trifecta (continence, potency and oncological result) has been the issue of discussions in recent years but lacking single center data for intra-institutional comparisons. Drouin and colleagues from Pitié-Salpétrière, University of Paris, France, compared the oncological midterm outcome over 50 months of patients treated during the same period in a single institution. Gilberti and colleagues from Savona, Italy present a prospective randomised trial including the mid-term follow-up data comparing brachytherapy with radical prostatectomy with regard to Trifecta.
As with any other surgical treatment option, laparoscopy carries the risk of major surgical complications. Teber and colleagues from Heilbronn, Germany, present their experience with identifying and treating ureteral injury during laparoscopic radical prostatectomy in their institutions series of more than 2,100 patients.
Rinnab and colleagues from the University of Ulm, Germany have been involved in detection methods for patients with biochemical recurrence after treatment of prostate cancer, which remains a diagnostic and therapeutic challenge. Here, they display their results on [(11)C] choline PET/CT in patients with biochemical recurrence after radical prostatectomy.
Androgen-deprivation therapy is associated with important adverse eVects which have an impact on quality of life, especially in men over 70 years of age. A further disadvantages of continuous application is the cost consideration. The high demand for deWnitive treatment of prostate cancer in older patient cohorts is a challenge for physicians. Many patients over 70 years of age regularly receive surgical treatment. PWtzenmayer and colleagues from the University of Heidelberg, Germany, report on survival of their patients in this category after radical prostatectomy in comparison to younger patients cohorts.
Treatment patterns, especially for high-risk or locally advanced cancer, have become a much-discussed topic lately. Jeong and colleagues from Seoul National University, Korea, focus on the eVect of concomitant pulmonary obstructed disease and its outcome after surgical treatment. Another article from Pitié-Salpétrière, University of Paris, France presented by Nyguen and colleagues focuses on the outcome of high-risk patients with a PSA level above 20 ng/ml. This issue presents a fascinating overview on diverse mainstream topics in prostate cancer and provides the reader with the most up-to-date scientiWc results in basic and clinical research.
